tbuckley/cabot-search huggingface dataset:
PTU-186 12 Month outcome and Patient Satisfaction with Structured Gastroenterological Evaluation for Chronic Gastrointestinal Symptoms following Pelvic Radiotherapy
Authors: C C Henson, J McLaughlin, Y Ang, C Babbs, J Crampton, M Kelly, S Lal, J K Limdi, G Whatley, R Swindell, W Makin, S E Davidson
Journal: Gut (2013)

<h3>Introduction</h3> Seventeen thousand patients are treated with radical pelvic radiotherapy annually in the UK.50% develop chronic GI symptoms. The structured approach to management used in this service evaluation has been shown to identify treatable diagnoses and improve symptoms in the short term. We report the first 12 month outcome data for the effect of structured gastroenterological evaluation on symptom burden and patient satisfaction. <h3>Methods</h3> Fifty-six patients with GI symptoms &gt; 6 months after radical pelvic radiotherapy underwent structured gastroenterological assessment as part of a service evaluation. They were assessed using the following questionnaires: inflammatory bowel disease questionnaire(IBDQ); Vaizey incontinence questionnaire (VIQ); and the Common Terminology Criteria for Adverse Events (CTCAE)pelvic symptom questionnaire.12 month assessments were compared to the previously reported baseline and 6 month assessments to determine if the improvement in symptoms was sustained. Patient satisfaction with the service was assessed at 12 months by an in-house questionnaire. <h3>Results</h3> Forty patients(71%)completed the 12 month assessment and 37(66%) completed the patient satisfaction questionnaire. The initial statistically significant improvement in GI symptoms from baseline to 6 months in parallel to GI evaluation was sustained up to 12 months in all questionnaires (IBDQ p = 0.019, IBDQB and CTCAE rectum bowel subset p &lt; 0.0005) except the VIQ (p = 0.098).There was also a clinically significant improvement as defined by an increase in IBDQ score of ≥0.5 points per question. Median total IBDQ and IBDQB score increased by 25 and 11 points respectively between baseline and 12 months.97% of patients found the appointments convenient, 97% felt their problems were understood; 86% were satisfied with the outcome and 89% with the service. Dissatisfaction related to communication (n = 3), travel (n = 2) and ongoing symptoms (n = 3). <h3>Conclusion</h3> The clinically and statistically significant improvement in GI symptoms found in parallel to structured gastroenterological evaluation for chronic GI symptoms following pelvic radiotherapy was sustained over 12 months follow up. These data suggest that structured investigation on the basis of the BSG guidelines can lead to a sustained improvement in symptoms and is acceptable to patients. Further research is essential to optimise patient care. <h3>Disclosure of Interest</h3> None Declared.
Deaths from adverse events are halved in Dutch hospitals
Authors: T. Sheldon
Journal: BMJ (2013)

The number of deaths from adverse events in hospitals in the Netherlands has halved during a national five year programme to improve safety, show figures from the country’s latest survey of harm related to care.

Researchers from the Institute for Health Services Research (NIVEL) and Amsterdam’s Free University Medical Centre looked at 4000 admissions among a representative sample drawn from 20 of the Netherlands’ 91 hospitals.

The study found …
USEFULNESS OF ADMIRE-HF RISK SCORE FOR THE PREDICTION OF SUDDEN CARDIAC DEATH IN PATIENTS WITH CHRONIC HEART FAILURE
Authors: Iyo Ikeda, Takahisa Yamada, Takashi Morita, Yoshio Furukawa, Shunsuke Tamaki, Yusuke Iwasaki, Masato Kawasaki, Atsushi Kikuchi, Takumi Kondo, Masashi Ishimi, Hideyuki Hakui, Tatsuhisa Ozaki, Yoshihiro Sato, Masahiro Seo, Eiji Fukuhara, Masatake Fukunami
Journal: Journal of the American College of Cardiology (2016)
PROGNOSTIC BENEFIT OF CARDIAC MAGNETIC RESONANCE OVER TRANSTHORACIC ECHOCARDIOGRAPHY FOR THE ASSESSMENT OF ISCHEMIC AND NON-ISCHEMIC DILATED CARDIOMYOPATHY PATIENTS REFERRED FOR PRIMARY PREVENTION IMPLANTABLE CARDIOVERTER DEFIBRILLATOR THERAPY
Authors: Gianluca Pontone, Daniele Andreini, Marco Guglielmo, Anna Solbiati, Saima Mushtaq, Andrea Baggiano, Virginia Beltrama, Virginia Beltrama, Cristina Rota, Andrea Igoren Guaricci, Mauro Pepi
Journal: Journal of the American College of Cardiology (2016)
P210 Which symptoms prompt patients with an exacerbation of COPD to persevere, self-treat or seek care? A comparison with health professionals
Authors: J. S. Wilson, J. J. Sittlington, E. McCrum-Gardner, F. Kee, J. S. Elborn
Journal: Thorax (2011)

<h3>Introduction and Objectives</h3> Exacerbations of Chronic Obstructive Pulmonary Disease are a major cause of morbidity and mortality. Despite the increased healthcare utilisation involved in treatment, little is known about how patients recognise an exacerbation. This study aims to identify the signs and symptoms that prompt patients to seek medical attention and also to identify which signs and symptoms health professionals expect patients to consider. <h3>Methods</h3> A Factorial Survey was used to create clinical vignettes describing a variety of signs and symptoms of an exacerbation. A total of 30 patients with Chronic Obstructive Pulmonary Disease (mean %FEV<sub>1</sub> 38.9) and 47 health professionals (14 GPs, 19 Specialist Nurses and 15 Respiratory Consultants/Registrars) completed a unique random set of vignettes. A total of 600 patient and 960 health professional vignettes were analysed using multiple regression analysis. <h3>Results</h3> There are substantial variations in the symptoms which patients regard as important prompts for action, compared to health professional expectations. Patients rely mainly on the colour and purulence of sputum (p&lt;0.001) as a cue for all possible actions, whereas health professionals expected patients to consider a variety of symptoms. <h3>Conclusion</h3> Many symptoms health professionals regard as important are not used to by patients to guide their decisions. As there is increasing focus on patients self-managing their disease, health professionals should exploit the symptoms patients already rely on rather than trying to change their behaviour.
Abstract P4-17-08: Tissue Expander/Implant Breast Reconstruction with and without Postmastectomy Radiation: Predictive Factors for Complications
Authors: SKA Nguyen, P Oxley, R Rastegar, M Joffres, W Kwan
Journal: Cancer Research (2012)

Abstract Purpose: 1) Review our complication rates with implant/expander reconstruction for breast cancer 2) Determine factors for complications, especially with postmastectomy radiation (PMRT) Materials and Methods: Data were collected through chart review of all patients (2004–2008) from an academic hospital undergoing implant/expander reconstruction. SAS was used for two or multi-variable analyses (logistic regression) to determine predictive factors for complications. Among PMRT patients, we evaluated complications rates by risk factors. Results: 237 patients underwent implant/expander reconstruction. Median time from implant placement until last follow-up was 173 days. 21.5% developed major complications (needing operative time or infection needing intravenous treatment). Diabetes was the most consistent factor associated with major complications (46.7 vs 20.1%, p = 0.02 and p = 0.009 in multivariable analysis). Radiation was linked to capsular contractures (18.6 vs 10.1%, p = 0.02). Chemotherapy (25.0 vs 19.0%, p = 0.26) or radiation (26.3 vs 19.1%, p = 0.21) did not predict major complications. Among patients receiving PMRT (80 patients), 26.2% had major complications, 34 had immediate PMRT on the expander and 44 had PMRT to the chest wall, followed by delayed reconstruction with expander/implant placement. In these, delayed reconstruction increased dehiscence (0 vs 18.2%, p = 0.009) compared to immediate reconstruction, with a trend for higher incidence of major complications in the delayed reconstruction group (14.7 vs 34.1%, p = 0.05). 40 Gy/16 versus 50–50.4 Gy/25-28 (28 vs 24%, p = 0.78) was not associated with major complications. Diabetes and smoking were associated with several complications. Conclusions: Diabetes is associated with a higher rate of major complications after expander/implant reconstruction while radiation increases capsular contractures. If PMRT is indicated, putting in an expander before radiation results in less morbidity than delayed reconstruction. Also, 40 Gy/16 versus 50–50.4 Gy/25-28 do not differ much in terms of complication rates. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P4-17-08.
Abstract 4021: Transcriptomic landscape of Ewing sarcoma based on RNAseq.
Authors: Ahmet Zehir, Srikanth R. Ambati, Malcolm AS Moore
Journal: Cancer Research (2013)

Abstract Ewing sarcoma is the second most common primary bone tumor in children, constituting 3% of all pediatric tumors. The 5 year survival rate is 59% to 76% for children younger than 15 years and from 20% to 49% for those aged 15 to 19 years. 85% of Ewing sarcoma are characterized by a chromosomal translocation between the Ewing sarcoma gene (EWS) breaking point and the ETS family of transcription factor FLI1, which creates a new type of fusion transcription factor with novel functions. While EWS-FLI1 is the predominating translocation event, other types of translocations between EWS and other ETS transcription factors have been reported. Mesenchymal stem cells (hMSC) are thought to be the cell of origin for Ewing sarcoma. The molecular mechanisms of transformation of hMSCs with ectopic EWS-FLI1 expression has been extensively studied, however, a complete transformation of hMSCs into Ewing sarcoma tumor cells is not yet achieved suggesting there are other elements required for the transformation of hMSCs. RNAseq has proved to be a powerful new method for capturing multiple arrays of information simultaneously such as gene expression, nucleotide variation, alternative splicing patterns and fusion transcripts. RNAseq has been used only once in the literature in identification of a novel fusion transcript in Ewing sarcoma tumor cells. Here we obtained RNAseq data from Ewing sarcoma patients and cell lines to gather novel insight into the pathogenesis of Ewing sarcoma. We obtained sequencing data from two Ewing sarcoma cell lines (A673 and SK-PN-DW); human brain vascular pericytes (HBVP), 8 patient tumors and 3 matched normal control tissues. Initial data analysis was performed through an in-house developed pipeline that uses publicly available software and further data analysis was performed using R with various packages. We describe the gene expression changes in patients compared to normal tissues as well as HBVP. We also discovered a group of novel fusion transcripts that we subsequently confirmed with RT-PCR. Since EWS is also an RNA splicing protein, changes in alternative splicing are also described. Citation Format: Ahmet Zehir, Srikanth R. Ambati, Malcolm AS Moore. Transcriptomic landscape of Ewing sarcoma based on RNAseq. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4021. doi:10.1158/1538-7445.AM2013-4021
Abstract 817: Genomic evolution landscape of patient tumor derived xenograft of gastric cancer.
Authors: Kun Yu, Swee Seong Wong, Jason C. Ting, Thompson N. Doman, Yong Yue, Amit aggarwal, Gregory P. Donoho, Rebekka Krumbach, Heiner H. Feibig, Seong-Ho kong, Woo-ho Kim, Han-kwang Yang, Christoph Reinhard
Journal: Cancer Research (2013)

Abstract Patient-derived xenograft (PDX) models have emerged as key model systems to understand the efficacy of anti-cancer agents. PDX systems have demonstrated superiority over cell lines with regards to higher histological resemblance to primary tumor, presence of stroma and also in mimicking response to therapeutic agents. However, the genomic evolution landscape of model establishment is not a well studied topic. In order to do that, we systematically collected materials from the first three passages of xenografts derived from eight gastric cancer patients from Seoul National University, Korea from 2008-2011. We subsequently generated comprehensive genomic profiles of the first three passages, parent primary tumor, and matched normal tissues for the eight patients. The genomic profiling data included whole-exome sequencing data (Agilent exome capture, paired-end sequencing on Illumina HiSeq 2000), mRNA expression (Affymetrix U133 Plus2.0), copy number data (Affymetrix SNP6), miRNA expression (Agilent miRNA array v16.0) and DNA methylation data (Illumina HumanMethylation27). The analysis is focused on two types of events: a) Cancer-related genomic changes derived from normal vs. tumor comparison, and their subsequent assessment in early passages; b) Passage-specific genomic changes derived from tumor vs. passages comparison. A further refinement of passage-specific genomic changes is done to differentiate ‘true’ passage-specific events from the ones that appear due to the difference in tumor purity that is lower in primary tumor due to the normal contamination. Overall, we describe the genomic landscape of evolution along xenograft establishment in gastric cancer and provide a comprehensive picture of genetic and genomic similarities (and differences) of xenografts to the primary tumor. This analysis will help us to better interpret the in vivo results emanating from experiments using xenografts and to translate the findings appropriately to the clinic. Citation Format: Kun Yu, Swee Seong Wong, Jason C. Ting, Thompson N. Doman, Yong Yue, Amit aggarwal, Gregory P. Donoho, Rebekka Krumbach, Heiner H. Feibig, Seong-Ho kong, Woo-ho Kim, Han-kwang Yang, Christoph Reinhard. Genomic evolution landscape of patient tumor derived xenograft of gastric cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 817. doi:10.1158/1538-7445.AM2013-817 Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
HIGH RISK OF MALIGNANT VENTRICULAR ARRHYTHMIAS IN CARDIAC SARCOIDOSIS ASSOCIATED WITH FAILURE TO SUPPRESS MYOCARDIAL INFLAMMATION ASSESSED BY FDG-PET SCANNING
Authors: Ashley Pender, Peter H.S. Sporn, Susan R. Russell, Rod Passman, Bradley Knight, Alexandru B. Chicos
Journal: Journal of the American College of Cardiology (2016)
New CIS Regions
Authors: J. Mathews
Journal: JNCI Journal of the National Cancer Institute (1993)

Journal Article New CIS Regions Get access James Mathews James Mathews Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 85, Issue 16, August 1993, Page 1279, https://doi.org/10.1093/jnci/85.16.1279 Published: 01 August 1993
The intracellular pathway for the presentation of vitamin B–related antigens by the antigen-presenting molecule MR1
Authors: Hamish E G McWilliam, Sidonia B G Eckle, Alex Theodossis, Ligong Liu, Zhenjun Chen, Jacinta M Wubben, David P Fairlie, Richard A Strugnell, Justine D Mintern, James McCluskey, Jamie Rossjohn, Jose A Villadangos
Journal: Nature Immunology (2016)
Abstract 755: FK506 binding protein 51 (FKBP51) binds to p300 and acts as transcriptional co-regulator of ABCG2 gene expression in melanoma.
Authors: Simona Romano, Giovanna Nappo, Elena Cesaro, Antonio Candela, Maria Fiammetta Romano
Journal: Cancer Research (2013)

Abstract Several lines of evidence support a role for FKBPs in chromatin modifications and cancer. Particularly for some of them, DNA association and regulation of gene expression has been demonstrated, mediated by histone- or transcription factor- chaperone activity. FKBP51 is an immunophilin that functions also as co chaperone of several proteins and receptors. We previously found this molecule has an essential role in melanoma resistance to the therapy and aggressiveness. Melanoma cells expressing stem cell markers (MCSC) produced high levels of FKBP51. In addition, the number of MCSC (identified by ABCG2 expression) was increased in FKBP51 over expressing melanoma cell lines. By converse, reduced expression of cancer stemness genes was measured in FKBP51 silenced melanoma. Since ABCG2+ cells also contained high levels of the general transcriptional co-activator, namely E1A binding protein p300, we hypotesized that FKBP51 might act as a p300 co chaperone with a role in transcriptional regulation of stemness markers. By co-IP assays, we show that FKBP51 interacts with p300 and partecipates in transcriptional complexes with Smad 2 and p300. By chromatin immunoprecipitation assays (ChIP) we demonstrate that FKBP51 binds to chromatin. We used different couples of primers to amplify different regions of the ABCG2 promoter, in FKBP51-immunoprecipitated chromatin and found enrichment of DNA fragments corresponding to a first sequence localized at 3450 bp (-3450) from the transcription start site (TSS), a second at -3219, and a third at -939. Differently, no enrichment in closest regions was found, suggesting the specificity of FKBP51 binding to ABCG2 promoter. In addition, we found p300 bound to the same regions of ABCG2 promoter, and such binding was impaired by FKBP51 downmodulation, suggesting the immunophilin regulatated the binding of p300 to DNA. In conclusion, our study supports the conclusion that FKBP51 partecipates in the transcriptional apparatus that controls expression of melanoma stemness genes, acting as co chaperone of p300. Citation Format: Simona Romano, Giovanna Nappo, Elena Cesaro, Antonio Candela, Maria Fiammetta Romano. FK506 binding protein 51 (FKBP51) binds to p300 and acts as transcriptional co-regulator of ABCG2 gene expression in melanoma. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 755. doi:10.1158/1538-7445.AM2013-755
OUTCOMES OF SIGNIFICANT TRICUSPID REGURGITATION AFTER CLOSURE OF ATRIAL SEPTAL DEFECT IN ADULTS
Authors: Jeong Yoon Jang, Jong-Min Song, Byeong Joo Bae, Se Hun Kang, Byung Joo Sun, Dae-Hee Kim, Duk-Hyun Kang, Jae-Kwan Song
Journal: Journal of the American College of Cardiology (2015)
THU0183 Cardiovascular Serious Adverse Events of Anti-TNF Therapies in Rheumatoid Arthritis: A Systematic Literature Review
Authors: C. Hong, R. Hughes, J. Galloway
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Background</h3> Research has shown increased TNF levels in heart failure (HF). Randomized controlled trials (RCT) have evaluated the effects of TNF inhibitors (TNFi) in these patients and failed to show benefit, and possibly even harm. This raised concerns about the use of TNFi in patients with RA and concomitant HF. <h3>Objectives</h3> The aim of this study was to explore the current available evidence to determine whether TNFi was associated with an increased risk of cardiac failure using data from both the RCTs of TNFi in HF as well as observational data from TNFi use in RA. <h3>Methods</h3> Two systematic reviews were performed: (1) Placebo controlled trials of TNFi therapy as a treatment for HF. (2) Studies of TNFi therapy in RA where data on HF as a specific outcome was published. Searches were performed using Ovid to search PUBMED and EMBASE. The TNFi therapies included in the literature search were adalimumab, etanercept, infliximab, certolizumab pegol and golimumab. Search (1) identified placebo RCTs of TNFi in HF published up until December 2012. Search (2) included RCTs and observational cohort studies and was limited to studies reporting rates for cardiac failure. Observational studies were required to be prospectively designed and with a comparator arm of non-biologic treated patients. <h3>Results</h3> Four RCTs were identified that have studied the effects of TNFi upon HF. Infliximab at 10mg/kg associated with a statistically significant increased risk of HF or death. None of the other RCTs showed a statistically significant difference. Meta-analysis showed a pooled hazard estimate of HF or death of 1.08 (95%CI 0.97, 1.20) with minimal heterogeneity (I<sup>2</sup> &lt; 0.0%). No RCTs of TNFi therapies in RA were identified that reported on HF as an outcome. The only available data available were from published results from five separate observational cohort studies. The pooled estimate of risk of HF from these studies was 0.98 (95%CI 0.85, 1.12), however with substantial heterogeneity (I<sup>2</sup> 71.7%). The studies differed in design, recruitment, length of follow up and outcome ascertainment. Substantial conflict was apparent, with point estimates varying both sides of unity. <h3>Image/graph</h3> <h3>Conclusions</h3> Despite animal and human studies highlighting the importance of TNF-α in HF, RCTs of TNFi failed to show any significant benefit and while the meta-analysis does not confirm a statistically significant risk of harm, the presence of a dose response is concerning. The published data in RA remains mixed, with significant heterogeneity in both study design and study results. Further research is urgently needed to clarify the risk of TNFi in patients with concomitant HF. The large observational registries around the world are in an ideal position to take this question further. <h3>Disclosure of Interest</h3> None Declared
Abstract 5288: Glioma stem cells stimulate the motility of brain endothelial cells: Identification of cell-adhesion molecules mediating motility and direct interaction
Authors: Monica E. Burgett, Russell S. Tipps, Justin D. Lathia, Shideng Bao, Jeremy N. Rich, Candece L. Gladson
Journal: Cancer Research (2012)

Abstract Angiogenesis is a prominent characteristic of malignant glioma. Glioma stem cells (GSCs) reside adjacent to blood vessels in the perivascular niche, and recent evidence suggests a role for GSCs in promoting angiogenesis. Here we examined the interplay between GSCs and endothelial cells (ECs) on a laminin substrate, and the potential for GSC promotion of EC motility. In an in vitro 2D motility assay, we found that GSCs dramatically stimulated EC migration, and ECs also stimulated GSC migration. An antibody to integrin α6 blocked in part the motility of both GSCs and ECs. We also found that GSCs directly interact with ECs; therefore, we investigated which cell-adhesion molecules mediated the interaction. In a cell-cell binding assay, blocking antibodies to both L1-cell adhesion molecule (L1CAM) and integrin αvβ3 inhibited in part the direct contact between GSCs and ECs. In the motility assay, the combination of antibodies to L1CAM and αvβ3 significantly inhibited the motility and interaction of both cell types. These data suggest GSCs can promote angiogenesis by promoting EC migration, and indicate a role for the cell-adhesion receptors L1CAM and αvβ3 in the direct interaction between GSCs and ECs that may promote EC motility. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 5288. doi:1538-7445.AM2012-5288
Idiopathic Avascular Necrosis of the Scaphoid in a Child Demonstrated by Bone Scintigraphy
Authors: WANZHEN ZENG, ALBERT DRIEDGER, WILLIAM PAVLOSKY, LORI BRUCE
Journal: Clinical Nuclear Medicine (2001)

ZENG, WANZHEN M.D., Ph.D.; DRIEDGER, ALBERT M.D., Ph.D.; PAVLOSKY, WILLIAM M.D.; BRUCE, LORI M.D. Author Information